New psoriasis shot shows promise in early safety trial
NCT ID NCT07051538
First seen Jan 29, 2026 · Last updated May 16, 2026 · Updated 19 times
Summary
This early-stage study tested a new drug called SHR-1139 in 64 people. First, healthy volunteers received a single shot or IV dose to check safety. Then, patients with moderate-to-severe plaque psoriasis got multiple shots. The main goal was to see if the drug is safe and how the body processes it. This is a first step toward finding a new treatment option for psoriasis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200031, China
Conditions
Explore the condition pages connected to this study.